StockNews.com Begins Coverage on vTv Therapeutics (NASDAQ:VTVT)

StockNews.com began coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a research report released on Wednesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Alliance Global Partners assumed coverage on shares of vTv Therapeutics in a research note on Monday, December 9th. They issued a “buy” rating and a $35.00 price objective for the company.

vTv Therapeutics Price Performance

NASDAQ VTVT opened at $16.66 on Wednesday. The business’s 50 day moving average price is $14.81 and its 200-day moving average price is $14.95. vTv Therapeutics has a fifty-two week low of $8.10 and a fifty-two week high of $30.99.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.88) earnings per share for the quarter.

Institutional Investors Weigh In On vTv Therapeutics

A hedge fund recently bought a new stake in vTv Therapeutics stock. FMR LLC purchased a new position in shares of vTv Therapeutics Inc. (NASDAQ:VTVT) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 178,200 shares of the biotechnology company’s stock, valued at approximately $2,402,000. FMR LLC owned approximately 5.92% of vTv Therapeutics at the end of the most recent quarter. 17.51% of the stock is owned by institutional investors and hedge funds.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.